ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Session » Sjögren's Syndrome: Clinical Aspects

Meeting: 2013 ACR/ARHP Annual Meeting

Abstract Number: 503
Sjögren’s Syndrome In American Ethnic and Racial Minorities
Abstract Number: 504
Raynaud’s Phenomenon and African American Race Are Independently Associated With Non-Hodgkin’s Lymphoma In Sjogrens Syndrome Patients: Findings From a United States National Study
Abstract Number: 505
Damage Accrual In a Single Centre Cohort Of Patients With Primary Sjögren’s Syndrome Followed Up For Over 10 Years
Abstract Number: 506
Hospitalization In Patients With Primary Sjögren’s Syndrome
Abstract Number: 507
Level Of Agreement Of The AECG 2002 and ACR 2012 Classification Criteria For Sjögren’s Syndrome In The Brittany Cohort: Clues To Understand Discrepancies
Abstract Number: 508
Is Ultrasonography Of Salivary Gland a Validate Tool In Sjögren Syndrome? Study 1: Interobserver Reliability Between International Group Of Experts
Abstract Number: 509
A Novel Screening Tool Indicative Of Primary Sjogren’s Syndrome Versus Sicca Symptoms
Abstract Number: 510
Multicentric Analysis Of Inter and Intra Observer Reliabilities For Histopathological Abnormalities In Salivary Gland Biopsy In Primary Sjögren Syndrome
Abstract Number: 511
Salivary Gland Lymphocyte Pattern Associated With Response To Belimumab In Primary sjogren’ssyndrome: Results Of The Beliss Study
Abstract Number: 512
The Significance Of Ectopic Germinal Center In Minor Salivary Gland Of Patients With Sjögren’s Syndrome
Abstract Number: 513
Diagnostic Value Of Labial Minor Salivary Gland Biopsy For Primary Sjögren’s Syndrome
Abstract Number: 514
EULAR Sjögren’s Syndrome Patient Reported Index (ESSPRI) Is Increased In Sjögren’s Syndrome Patient With Fibromyalgia
Abstract Number: 515
Does Multiplex Flow Immunoassay Underdetect SSA and SSB Antibodies? An Evaluation Of The Sjogren’s International Collaborative Clinical Alliance (SICCA) Cohort
Abstract Number: 516
Prevalence Of Seronegative Sjogren’s Syndrome: A Comparative Study From The Sjogren’s International Collaborative Clinical Alliance (SICCA) Cohort
Abstract Number: 517
Antibody Responses To Oral Bacteria In Patients With Primary Sjögren’s Syndrome and Comparison With Rheumatoid Arthritis and Periodontitis
Abstract Number: 518
Vitamin D In Sjogren’s Syndrome
Abstract Number: 519
Identification Of IgG4-Related Disease and Analysis Of IgG4 Serum Levels In Different Subgroups Of Patients With Sjögren’s Syndrome
Abstract Number: 520
Chronic Obstructive Pulmonary Disease Is Very Common in Primary Sjögren’s Syndrome
Abstract Number: 521
Respiratory Compromise In Patients With Primary Sjögren Syndrome
Abstract Number: 522
Abatacept Reduces Disease Activity In Early Primary Sjögren’s Syndrome:One Year Results From a Phase II Open-Label Study

« View all sessions from this meeting

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under embargo once the ACR has notified ­­­presenters of their abstract’s acceptance, and cannot be presented at other meetings after this time. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until November 7 at 10:00 AM ET. Journalists with access to embargoed information also cannot release articles before this time.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Permissions and Reprints

For information about abstract permissions and reprints, see ACR Convergence permissions and reprint policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2023 American College of Rheumatology